A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
Clinical trial NCT02720510 · TERMINATED
Trial details
- NCT number
- NCT02720510
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-14
- Primary completion
- 2017-05-22
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.